AAV1-FS344

Drug Profile

AAV1-FS344

Alternative Names: AAV1-Follistatin; Gene therapy-delivered myostatin inhibitor (AAV1-FS344) – Milo Biotechnology; rAAV1 CMV huFollistatin 344; rAAV1.CMV.huFollistin344

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Milo Biotechnology; Nationwide Children's Hospital
  • Class Gene therapies
  • Mechanism of Action Follistatin stimulants; Gene transference; Myostatin inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Inclusion body myositis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Duchenne muscular dystrophy; Inclusion body myositis

Most Recent Events

  • 04 Oct 2016 AAV1-FS344 receives Orphan Drug status for Inclusion body myositis in USA
  • 01 Jan 2015 Phase-I/II clinical trials in Duchenne muscular dystrophy (In children, In adolescents, In adults) in USA (IM) (NCT02354781)
  • 03 Dec 2014 Milo Biotechnology has patent protection for AAV1-FS344 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top